Fibrogen Inc CS (FGEN)

$7.15 -0.20 (-2.72%)
Market Cap 29.71M
Revenue (ttm) 29.62M
Net Income (ttm) -47.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.63%
Debt to Equity Ratio -0.37
Volume 59,800
Avg Vol 46,913
Day's Range N/A - N/A
Shares Out 4.04M
Stochastic %K 80%
Beta 0.74
Analysts Sell
Price Target $250.00

Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 978 1200
Fax: 415 978 1902
Address:
350 Bay Street, Suite 10 #6009, San Francisco, United States
MaxMiamiFl
MaxMiamiFl Jul. 12 at 9:14 PM
$FGEN Under the terms of the agreement, FibroGen will receive an enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 million, totaling approximately $160 million. The transaction is expected to close by mid-2025
0 · Reply
MaxMiamiFl
MaxMiamiFl Jul. 12 at 9:12 PM
$FGEN Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS), a high-value indication with significant unmet medical need. The Company is planning for an FDA meeting in the second quarter of 2025 to determine the potential next steps for the development program for roxadustat in the U.S
0 · Reply
trader013
trader013 Jul. 11 at 8:08 PM
$FGEN Are we heading to the Moon or ...
1 · Reply
MaxMiamiFl
MaxMiamiFl Jul. 11 at 6:38 PM
$FGEN MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy from $7 to $67................. FGEN do the same!!!!!!!!
0 · Reply
MarketWarfare
MarketWarfare Jul. 11 at 5:07 PM
$FGEN look at ticker INKT. A perennial shit stock just like fgen, soaring 800% today. Just need the right announcement....
1 · Reply
Value10
Value10 Jul. 11 at 2:17 PM
$FGEN I think China Approval is coming soon; and I expect the stock to move to $25 to $35 a share overnight, if announcement is after hours. Not higher, because a lot of burned shareholders and traders will Sell instantly. However, I will hold to see what CEO announces next after the China Sale… I do not care about the remaining drug pipeline… other than what it is worth when another company comes-in, which I believe will be announced soon after China Sale. That will move stock to its true value at that point… maybe $65 to $70 which would be around $250 million market cap at that point.
0 · Reply
crackdeed
crackdeed Jul. 11 at 4:30 AM
$FGEN 10%>20%>3️⃣0️⃣%⁉️
1 · Reply
StockScanners
StockScanners Jul. 11 at 2:47 AM
$FGEN Keep watch if this holds above 5.75
0 · Reply
Value10
Value10 Jul. 10 at 11:03 PM
$FGEN I sure hope the China Sale is approved soon… It is GREAT timing if approved soon… cuz we get all the Cash made up until the Approval, and generic-drugs will be starting in China… great time to exit now. FGEN may clear $225 million liquid cash from the Sale. The pay Morgan Stanley and still have $150 million Cash… with only a $30 million market-cap
1 · Reply
Waikiki2010
Waikiki2010 Jul. 10 at 9:32 PM
$FGEN The closing of the China deal is , maybe, about to hit the news and somebody knowledgeable of it is taking early positions on the stock. IMO.
2 · Reply
Latest News on FGEN
Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Jun 13, 2025, 8:22 AM EDT - 4 weeks ago

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

ADBE

FibroGen Announces 1-for-25 Reverse Stock Split

Jun 12, 2025, 4:02 PM EDT - 4 weeks ago

FibroGen Announces 1-for-25 Reverse Stock Split

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

Jun 9, 2025, 4:02 PM EDT - 4 weeks ago

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 10:31 PM EDT - 2 months ago

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:02 PM EDT - 2 months ago

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

May 8, 2025, 4:24 AM EDT - 2 months ago

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

FibroGen to Report First Quarter 2025 Financial Results

May 5, 2025, 4:05 PM EDT - 2 months ago

FibroGen to Report First Quarter 2025 Financial Results

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 4:05 PM EDT - 3 months ago

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 8:18 PM EDT - 4 months ago

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 17, 2025, 4:05 PM EDT - 4 months ago

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:45 PM EST - 4 months ago

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

Feb 20, 2025, 1:08 PM EST - 5 months ago

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

AZN

FibroGen sells China unit to AstraZeneca in deal worth $160 million

Feb 20, 2025, 6:40 AM EST - 5 months ago

FibroGen sells China unit to AstraZeneca in deal worth $160 million

AZN

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Feb 20, 2025, 6:30 AM EST - 5 months ago

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

FibroGen Appoints David DeLucia as Chief Financial Officer

Dec 16, 2024, 8:05 AM EST - 7 months ago

FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

Nov 12, 2024, 8:38 PM EST - 8 months ago

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

FibroGen Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 8 months ago

FibroGen Reports Third Quarter 2024 Financial Results

FibroGen to Report Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 8 months ago

FibroGen to Report Third Quarter 2024 Financial Results

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 11:32 AM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

Jul 31, 2024, 12:33 PM EDT - 1 year ago

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

FibroGen to Report Second Quarter 2024 Financial Results

Jul 30, 2024, 4:07 PM EDT - 1 year ago

FibroGen to Report Second Quarter 2024 Financial Results

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

Jun 6, 2024, 12:38 PM EDT - 1 year ago

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

Jun 3, 2024, 4:05 PM EDT - 1 year ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

Jun 3, 2024, 4:02 PM EDT - 1 year ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

May 23, 2024, 5:05 PM EDT - 1 year ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

FibroGen to Participate in Upcoming Investor Conferences

May 7, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Participate in Upcoming Investor Conferences

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

May 6, 2024, 10:31 PM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

FibroGen Reports First Quarter 2024 Financial Results

May 6, 2024, 4:02 PM EDT - 1 year ago

FibroGen Reports First Quarter 2024 Financial Results

FibroGen to Report First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Report First Quarter 2024 Financial Results

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

Apr 24, 2024, 4:02 PM EDT - 1 year ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Apr 2, 2024, 5:46 PM EDT - 1 year ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Mar 11, 2024, 7:00 AM EDT - 1 year ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 11:44 PM EST - 1 year ago

FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript

FibroGen regains rights to anemia drug from AstraZeneca

Feb 26, 2024, 4:18 PM EST - 1 year ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 4:06 PM EST - 1 year ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

Feb 26, 2024, 4:05 PM EST - 1 year ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 20, 2024, 7:00 AM EST - 1 year ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Feb 5, 2024, 7:00 AM EST - 1 year ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Jan 25, 2024, 7:00 AM EST - 1 year ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Dec 9, 2023, 5:02 PM EST - 1 year ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 8:30 PM EST - 1 year ago

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

FibroGen Reports Third Quarter 2023 Financial Results

Nov 6, 2023, 4:01 PM EST - 1 year ago

FibroGen Reports Third Quarter 2023 Financial Results

FibroGen to Report Third Quarter 2023 Financial Results

Oct 23, 2023, 7:00 AM EDT - 1 year ago

FibroGen to Report Third Quarter 2023 Financial Results

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Sep 27, 2023, 1:00 PM EDT - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

FibroGen shares fall after failure in late-stage study of Duchenne muscular dystrophy treatment

Aug 30, 2023, 7:55 AM EDT - 2 years ago

FibroGen shares fall after failure in late-stage study of Duchenne muscular dystrophy treatment

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

Aug 29, 2023, 4:15 PM EDT - 2 years ago

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

MaxMiamiFl
MaxMiamiFl Jul. 12 at 9:14 PM
$FGEN Under the terms of the agreement, FibroGen will receive an enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 million, totaling approximately $160 million. The transaction is expected to close by mid-2025
0 · Reply
MaxMiamiFl
MaxMiamiFl Jul. 12 at 9:12 PM
$FGEN Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS), a high-value indication with significant unmet medical need. The Company is planning for an FDA meeting in the second quarter of 2025 to determine the potential next steps for the development program for roxadustat in the U.S
0 · Reply
trader013
trader013 Jul. 11 at 8:08 PM
$FGEN Are we heading to the Moon or ...
1 · Reply
MaxMiamiFl
MaxMiamiFl Jul. 11 at 6:38 PM
$FGEN MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy from $7 to $67................. FGEN do the same!!!!!!!!
0 · Reply
MarketWarfare
MarketWarfare Jul. 11 at 5:07 PM
$FGEN look at ticker INKT. A perennial shit stock just like fgen, soaring 800% today. Just need the right announcement....
1 · Reply
Value10
Value10 Jul. 11 at 2:17 PM
$FGEN I think China Approval is coming soon; and I expect the stock to move to $25 to $35 a share overnight, if announcement is after hours. Not higher, because a lot of burned shareholders and traders will Sell instantly. However, I will hold to see what CEO announces next after the China Sale… I do not care about the remaining drug pipeline… other than what it is worth when another company comes-in, which I believe will be announced soon after China Sale. That will move stock to its true value at that point… maybe $65 to $70 which would be around $250 million market cap at that point.
0 · Reply
crackdeed
crackdeed Jul. 11 at 4:30 AM
$FGEN 10%>20%>3️⃣0️⃣%⁉️
1 · Reply
StockScanners
StockScanners Jul. 11 at 2:47 AM
$FGEN Keep watch if this holds above 5.75
0 · Reply
Value10
Value10 Jul. 10 at 11:03 PM
$FGEN I sure hope the China Sale is approved soon… It is GREAT timing if approved soon… cuz we get all the Cash made up until the Approval, and generic-drugs will be starting in China… great time to exit now. FGEN may clear $225 million liquid cash from the Sale. The pay Morgan Stanley and still have $150 million Cash… with only a $30 million market-cap
1 · Reply
Waikiki2010
Waikiki2010 Jul. 10 at 9:32 PM
$FGEN The closing of the China deal is , maybe, about to hit the news and somebody knowledgeable of it is taking early positions on the stock. IMO.
2 · Reply
MaTroSe
MaTroSe Jul. 10 at 8:39 PM
$FGEN big move today. Fantastic!!! But why?
2 · Reply
Value10
Value10 Jul. 10 at 6:55 PM
$FGEN Volume of stock trading today is incredible… 220,000 shares pre-RS would have been 6 (six)-Million Shares pre-split, which never occurred daily back then. Or, look at it this way… more than 6% of the TOTAL company’s stock has traded today while the stock moves upwards 25%…. Market-cap increased 50% in one week… $20-million to $30-million… and mathematically even $30-million market-cap is too low… Some investors thought… “wait a minute, is this correct, if they liquidated we would get more than $20-Million in market-cap payout… okay, I’ll buy”…
0 · Reply
RollingDollars
RollingDollars Jul. 10 at 6:46 PM
$FGEN
0 · Reply
RollingDollars
RollingDollars Jul. 10 at 4:46 PM
$FGEN
0 · Reply
eneub87
eneub87 Jul. 10 at 4:36 PM
$FGEN 18% to break even! Lfg
1 · Reply
Value10
Value10 Jul. 10 at 4:35 PM
$FGEN Twenty (20%) percent move upwards on triple (300%) the average daily volume… BEFORE NOON TIME!… Following yesterday’s 10% up move on double (200%) the average volume… Short-squeeze AND some investors were just waiting for the last nervous Sellers to leave…
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jul. 10 at 4:26 PM
$FGEN come on $32!!!!
0 · Reply
MaxMiamiFl
MaxMiamiFl Jul. 10 at 3:41 PM
$FGEN lo I sold a few at 6.50 look at this shit. lol oh well, any green is good green. got them at 5.95
1 · Reply
deerix
deerix Jul. 10 at 3:00 PM
$FGEN Fuck that's 20% from my post. Maybe I should have just entered. This will be on my watchlist still.
1 · Reply
Value10
Value10 Jul. 9 at 8:31 PM
$FGEN Ten (10%) percent stock price gain today on double (200%) the average trade volume… That is “building a base floor on the price” and squeezing the shorts. China Sale gets approved and this stock price is $20 (twenty) dollars overnight:
0 · Reply
DavidDayTrade
DavidDayTrade Jul. 9 at 7:14 PM
$FGEN LOOKS READY, POST R/S HAVEN'T' RUN YET
1 · Reply
MaxMiamiFl
MaxMiamiFl Jul. 9 at 4:58 PM
$FGEN someone just made this lol https://www.youtube.com/shorts/Chq17gc6U84
1 · Reply